What it's for (Indications)
- Flupenthixol + melitracen is a fixed-dose combination medication primarily indicated for the treatment of anxiety-depressive states, particularly those characterized by symptoms such as anxiety, apathy, dysphoria, fatigue, and lack of drive.
- This combination is often prescribed for neurotic depressions, psychogenic depressions, masked depression, and psychosomatic affections where anxiety and depressive symptoms co-exist.
- Its utility lies in addressing both the anxiolytic and activating properties provided by low-dose flupenthixol and the mood-elevating and antidepressant effects of melitracen.
- The drug aims to alleviate emotional distress, improve mood, and restore functional capacity in patients experiencing mild to moderate forms of depression and anxiety, especially when conventional single-agent therapies may not provide adequate relief or when there is a need for a rapid onset of anxiolytic and activating effects alongside antidepressant action.
- This comprehensive approach is designed to manage the complex interplay of emotional and physical symptoms often observed in these conditions, providing relief from both the psychological burden and associated somatic complaints.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of flupenthixol + melitracen must be individualized based on the patient's clinical condition, severity of symptoms, and response to treatment. Typically, for adults, the recommended starting dose is one tablet (e.g., 0.5 mg flupenthixol and 10 mg melitracen) once or twice daily. The daily dosage should generally not exceed two tablets per day, especially in the initial phases of treatment. It is crucial to commence with the lowest effective dose and titrate upwards cautiously, if necessary, under strict medical supervision. Elderly patients, individuals with impaired hepatic or renal function, or those with underlying cardiovascular conditions may require lower doses and careful monitoring due to increased sensitivity and potential for adverse effects. Abrupt discontinuation should be avoided; instead, the dosage should be gradually reduced over several weeks to minimize the risk of withdrawal symptoms such as nausea, vomiting, sweating, headache, tremor, anxiety, and insomnia. Adherence to prescribed dosing is essential for both efficacy and safety, and patients should be advised against self-adjusting their medication without consulting their healthcare provider. |
Safety & Warnings
Common Side Effects
- Flupenthixol + melitracen, being a combination of a typical antipsychotic and a tricyclic antidepressant, carries a broad spectrum of potential side effects, reflecting the pharmacological profiles of both components.
- Common adverse reactions include anticholinergic effects such as dry mouth, blurred vision, constipation, and urinary retention.
- Central nervous system effects can manifest as sedation, drowsiness, dizziness, insomnia, restlessness, or agitation.
- Extrapyramidal symptoms (EPS), including tremor, akathisia (inner restlessness), dystonia, and parkinsonism, are possible, even at the low doses of flupenthixol used in this combination.
- Cardiovascular side effects may include tachycardia, orthostatic hypotension (a drop in blood pressure upon standing), and ECG changes such as QTc prolongation, which increases the risk of serious arrhythmias.
- Other reported side effects include weight gain, sexual dysfunction, headache, nausea, dyspepsia, and fatigue.
- More serious, albeit rare, adverse events include Neuroleptic Malignant Syndrome (NMS), characterized by fever, muscle rigidity, altered mental status, and autonomic instability; tardive dyskinesia, which involves involuntary movements, especially of the face and tongue; seizures; blood dyscrasias (e.
- g.
- , agranulocytosis with TCAs); and hepatotoxicity.
- Patients should be informed about these potential side effects and advised to report any concerning symptoms to their healthcare provider promptly for evaluation and management.
Serious Warnings
- Black Box Warning: **WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis and Suicidality in Children, Adolescents, and Young Adults.** **Increased Mortality in Elderly Patients with Dementia-Related Psychosis:** Flupenthixol, an antipsychotic component of this combination, is associated with an increased risk of death when used in elderly patients with dementia-related psychosis. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotics, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times that in placebo-treated patients. Although the causes of death were varied, most fatalities appeared to be cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Flupenthixol + melitracen is not approved for the treatment of dementia-related psychosis. **Suicidality in Children, Adolescents, and Young Adults:** Melitracen, a tricyclic antidepressant (TCA) component of this combination, belongs to a class of drugs that have been associated with an increased risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (ages 18-24) in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. This risk extends to a lesser degree to patients of all ages, and patients should be closely monitored for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial stages of treatment or following dose adjustments. Families and caregivers should be alerted to the need for close observation and communication with the prescribing physician regarding any emergent suicidal ideation or behavioral changes. This medication is not approved for use in pediatric patients.
- Several significant warnings are associated with the use of flupenthixol + melitracen due to the pharmacological properties of its components.
- Caution is advised in elderly patients, who are generally more susceptible to anticholinergic effects, orthostatic hypotension, and central nervous system side effects, increasing their risk of falls, delirium, and other complications.
- Patients with pre-existing cardiovascular conditions, including a history of myocardial infarction, arrhythmias, or congestive heart failure, should be monitored closely due to the potential for QTc prolongation and other adverse cardiac events.
- The medication can lower the seizure threshold, necessitating caution and dose adjustment in patients with a history of epilepsy or other seizure disorders.
- Due to its anticholinergic properties, it should be used with care in patients with narrow-angle glaucoma or conditions predisposing to urinary retention, such as prostatic hypertrophy.
- Abrupt cessation of treatment can lead to withdrawal symptoms, including nausea, vomiting, sweating, headache, tremor, anxiety, and insomnia; therefore, gradual tapering of the dosage is recommended to minimize these effects.
- Concurrent use with alcohol or other central nervous system depressants should be avoided due to additive sedative effects, which can impair cognitive function and motor skills.
- Patients should be warned about impaired ability to drive or operate hazardous machinery.
- Furthermore, individuals with severe hepatic or renal impairment may require dose adjustments and careful monitoring given the metabolic pathways of these drugs and the potential for accumulation.
- The potential for precipitation of mania or hypomania in susceptible individuals should also be considered.
How it Works (Mechanism of Action)
The therapeutic efficacy of flupenthixol + melitracen stems from the synergistic actions of its two active pharmaceutical ingredients, targeting distinct but complementary neurotransmitter systems. Flupenthixol, a thioxanthene derivative, primarily acts as a first-generation antipsychotic, functioning as an antagonist at dopamine D1 and D2 receptors in the brain. At the low doses utilized in this combination, flupenthixol is thought to exert anxiolytic and activating effects, rather than its typical antipsychotic properties, by selectively modulating dopaminergic activity in specific brain regions, such as the mesolimbic and mesocortical pathways, contributing to an improvement in apathy, lack of initiative, and drive. Melitracen, a tricyclic antidepressant (TCA), primarily works by inhibiting the reuptake of both norepinephrine and serotonin in the central nervous system. This dual reuptake inhibition leads to increased concentrations of these key neurotransmitters in the synaptic cleft, thereby enhancing their availability for neuronal signaling. The increased synaptic levels of norepinephrine and serotonin are believed to underpin melitracen's antidepressant and anxiolytic effects. The combination aims to provide a balanced approach, with flupenthixol addressing symptoms like lack of initiative and anxiety, and melitracen targeting the core depressive symptoms, thereby offering comprehensive relief for mixed anxiety-depressive states by modulating multiple neurochemical pathways involved in mood, anxiety, and motivation.
Commercial Brands (Alternatives)
No other brands found for this formula.